Prelude Capital Management, LLC Nu Cana PLC Transaction History

Prelude Capital Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$4.4 - $5.59 $88,000 - $111,800	-20,000 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$4.57 - $6.48 $91,400 - $129,600	20,000 New	20,000 $103,000
Q4 2018 Feb 14, 2019	SELL	$13.0 - $22.57 $510,562 - $886,414	-39,274 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$20.12 - $26.86 $301,840 - $402,953	15,002 Added 61.81%	39,274 $979,000
Q2 2018 Aug 14, 2018	BUY	$19.0 - $29.84 $51,433 - $80,776	2,707 Added 12.55%	24,272 $461,000
Q1 2018 May 15, 2018	BUY	$10.04 - $28.25 $216,512 - $609,211	21,565 New	21,565 $408,000

3.34M

Ticker NCNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,196,000
Market Cap $133M
Description
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients ...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.